Surgical Robots, Medications, and Production Expansion! J&J has delivered and is likely to hit the $100 billion mark!

Has Johnson & Johnson (i)(JNJ) delivered in the second quarter of 2026? For me, the clear answer is: Yes! Although Wall Street reacted cautiously to the numbers, the foundation of the healthcare giant is rock solid. With a reported revenue growth of 6.6% to $25.3 billion, expectations were met. The adjusted earnings per share of $2.90 even exceeded forecasts by $0.05. The Innovative Medicine segment performed particularly well, climbing 7.8% to $16.4 billion, driven by successes in oncology with Darzalex and the psoriasis medication Tremfya....